We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | NASDAQ:EGRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 5.01% | 4.40 | 4.40 | 4.65 | 4.64 | 4.18 | 4.18 | 99,757 | 22:53:43 |
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (NASDAQ:EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, David Riggs, Chief Financial Officer, and other members of Eagle's senior management team will host an Investor Day in New York City on November 11, 2016.
The event will focus on the Company's growth initiatives, R&D pipeline and financial outlook. It will provide additional insight on Ryanodex® for Exertional Heat Stroke and Methamphetamine and Ecstasy Intoxication, recent product launches and new growth opportunities.
Event: Eagle Pharmaceuticals Investor DayDate: November 11, 2016Time: 8:00 a.m. ET to 11:30 a.m. ET (registration and breakfast begin at 7:00 a.m. ET).Location: The Pierre 2 East 61st Street, New York City
Institutional investors and analysts who wish to register can RSVP to Lisa Wilson, Investor Relations for Eagle Pharmaceuticals, either via telephone at 1-212-452-2793 or e-mail at lwilson@insitecony.com.
An audio webcast of the presentation will be available by visiting the Investor Relations section of Eagle Pharmaceuticals web site at www.eagleus.com. A replay of the presentation will be available for 90 days.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160927006682/en/
Investor Relations for Eagle Pharmaceuticals, Inc.In-Site CommunicationsLisa Wilson, 212-452-2793
1 Year Eagle Pharmaceuticals Chart |
1 Month Eagle Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions